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Objective: To determine the effect of radiofrequency catheter ablation (RFA) on progression of paroxysmal atrial fibrillation (AF).
Background:  Progression to persistent AF may occur in up to 50% of patients with paroxysmal AF receiving pharmacological therapy. Hypertension, 
age, prior transient ischemic event, chronic obstructive pulmonary disease, and heart failure (HATCH score) have been identified as independent risk 
factors for progression of AF.
Methods:  RFA was performed in 504 patients (mean age: 58±10 years) to eliminate paroxysmal AF. A repeat RFA procedure was performed in 193 
patients (38%). Clinical variables predictive of outcome and their relation to progression of AF after RFA were assessed using multivariate analysis
Results:  At a mean follow-up of 27±12 months after RFA, 434/504 patients (86%) were in sinus rhythm; 49/504 patients (9.5%) continued to 
have paroxysmal AF; and 14 (3%) were in atrial flutter. Among the 504 patients, 7 (1.5%) progressed to persistent AF. In patients with recurrent 
AF after RFA, paroxysmal AF progressed to persistent AF in 7/56 (13%, P<0.001). The progression rate of AF was 0.6% per year after RFA (P<0.001 
compared to 9% per year reported in pharmacologically treated patients). Age>75 years, duration of AF >10 years and diabetes were independent 
predictors of progression to persistent AF. The HATCH score was not significantly different between patients with paroxysmal AF who did and did not 
progress to persistent AF (0.7±0.8vs. 1.0±0.5, P=0.3).
Conclusions:  Compared to a historical control group of pharmacologically-treated patients with paroxysmal AF, RFA appears to reduce the rate of 
progression of paroxysmal AF to persistent AF. Age, duration of AF, and diabetes are independent risk factors for progression to persistent AF after RFA. 
HATCH score is not predictive of progression of paroxysmal AF after the RFA and should not be used in patient selection for RFA.
